vimarsana.com

Page 40 - நாஸ்டாக் முதல் வடக்கு வளர்ச்சி சந்தை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FSS selects Zwipe Pay ONE for Next-Generation Contactless Cards to be offered globally

Share this article Share this article OSLO, Norway and CHENNAI, India, May 10, 2021 /PRNewswire/ FSS (Financial Software and Systems), a leading global provider of integrated payment products and a payment processor, is partnering with Zwipe to bring next generation contactless payment cards to issuers globally. Zwipe is a payment FinTech recognized for having pioneered the development of biometric payments and has delivered many successful pilots around the world. FSS is among the leading providers of card issuance products globally and its card portfolio consists of 800 plus million payment cards for Tier One banks and payment processors. The organizations will collaborate closely, offering greater value to customers by combining FSS s Unified Issuance Platform and Zwipe Pay One biometric card capabilities, supported by Zwipe s fast-growing global network of card manufacturing partners.

Nasdaq Nordic: Nasdaq Copenhagen welcomes Digizuite A/S to Nasdaq First North Growth Market

Nasdaq Nordic: Nasdaq Copenhagen welcomes Digizuite A/S to Nasdaq First North Growth Market Copenhagen May 7, 2021 - Nasdaq (Nasdaq: NDAQ) announces that trading in the Digizuite share (short name: DIGIZ) starts today on Nasdaq First North Growth Market Denmark. Digizuite belongs to the technology sector and is the 8th company which will be admitted to trading on Nasdaq Copenhagen in 2021 and is the 47th company on the Nasdaq Nordic Market . Digizuite is a global software company that has developed and sells a cloud-based Digital Asset Management solution that makes it easy and efficient for companies to manage, optimize and automate workflows in connection with

Nexstim Oyj: Nexstim Receives a New NBS System Order from a Leading California Based Academic Hospital

Nexstim Oyj: Nexstim Receives a New NBS System Order from a Leading California Based Academic Hospital Hospital Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that it has received an NBS system order from a distinguished academic hospital based in Northern California, US. Nexstim NBS systems use the unique SmartFocus TMS technology that enables accurate stimulation of the targeted area in the brain. The Nexstim NBS system is the only FDA cleared system based on navigated Transcranial Magnetic Stimulation (nTMS) for non-invasive mapping of the speech and motor cortices of the brain. Mikko Karvinen, CEO of Nexstim, says:

Correction: Arcane Crypto Interim report January - March 2021

Message : Required fields Arcane Crypto AB today published its first quarter report for year 2021 and it is available on the company s investor relation website http://investor.arcanecrypto.se/. Main events during the first quarter 2021 On 11th January 2021, the Extraordinary General Meeting of Vertical Ventures AB (publ) approved the acquisition of Arcane Crypto AS. The acquisition was completed on the same day. On 15th January 2021, Torbjørn Bull Jenssen was appointed CEO of Vertical Ventures AB (publ). On 4th February 2021, Vertical Ventures AB (publ) changed its name to Arcane Crypto AB. On 5th February 2021, Arcane Crypto AB completed its listing on Nasdaq First North Growth Market and had its first day of trading.

Nexstim Receives a New NBS System Order from a Leading

About Nexstim Plc Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders. Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain. SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.